Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Mammal patents



      

This page is updated frequently with new Mammal-related patent applications.




Date/App# patent app List of recent Mammal-related patents
07/21/16
20160208309 
 In vitro  estimating in vivo protein digestibility patent thumbnailIn vitro estimating in vivo protein digestibility
An analysis technique can be performed to quantify the digestible protein content of a protein-containing sample outside the body of a living organism. Traditionally, protein digestibility is evaluated in vivo, for example using a rat subject to measure protein digestibility after being fed the protein-containing sample.
General Mills, Inc.


07/21/16
20160208286 
 Alphaviral vectors and cell lines for producing recombinant proteins patent thumbnailAlphaviral vectors and cell lines for producing recombinant proteins
The present invention relates to polynucleotides and alphaviral vectors for the expression of genes of interest in mammalian cells. Additionally, the invention relates to cells which comprise said polynucleotides and alphaviral vectors and are capable of stably expressing one or more genes of interest.
3p Biopharmaceuticals, S.l.


07/21/16
20160208261 
 Methods and compositions for inhibiting the function of polynucleotide sequences patent thumbnailMethods and compositions for inhibiting the function of polynucleotide sequences
A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded rna molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This rna molecule desirably does not produce a functional protein.
Alnylam Pharmaceuticals, Inc.


07/21/16
20160208235 
 Detection and removal of misfolded proteins/peptides patent thumbnailDetection and removal of misfolded proteins/peptides
The invention concerns the field of detecting and quantifying misfolded proteins/peptides. In particular the detection and quantification of misfolded proteins/peptides in body fluids, on cell surfaces of humans and mammals, the detection of misfolded proteins/peptides in reagents to be tested for scientific research and/or diagnostic use and in pharmaceutical medication or their additives and it concerns as well the removal of misfolded proteins/peptides from reagents to be tested for scientific research and/or for diagnostic purposes and from pharmaceutical medication or their additives.
Oxprotect Gmbh


07/21/16
20160208011 
 Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same patent thumbnailCcr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating ccr3, e.g., by modulating eotaxin-1/ccr3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment.
The United States Government As Represented By The Department Of Veterans Affairs


07/21/16
20160208000 
 Immunoreceptor modulation for treating cancer and viral infections patent thumbnailImmunoreceptor modulation for treating cancer and viral infections
A method of reducing or relieving immune inhibition in a mammal includes the step of at least partly inhibiting or reducing cd96 activity in one or more cells of the mammal to thereby relieve immune inhibition and/or enhance or restore immune surveillance in the mammal. Typically, inhibiting or reducing cd96 activity does not include, or depend upon, killing of cd96-expressing cells in the mammal.
The Council Of The Queensland Institute Of Medical Research


07/21/16
20160206773 
 Composition and  stopping hemorrhage, infection, and accelerating healing in various types of wound or burns patent thumbnailComposition and stopping hemorrhage, infection, and accelerating healing in various types of wound or burns
A composition and a method of applying the composition to a site on or within a body of a mammal. The composition includes a hydrogel matrix that includes at least one polymer cross linked, via ionic or covalent bonding, with both hyaluronic acid and alginic acid.

07/21/16
20160206749 
 Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells patent thumbnailMethods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
Cholesterol moieties are linked to specific ends of double-stranded rna, preferably a small, interfering (si)rna or to a dshybrid. The dshybrid has one strand comprised of dna and one strand comprised of rna.
Marina Biotech, Inc.


07/21/16
20160206723 
 Bacterial artificial chromosomes patent thumbnailBacterial artificial chromosomes
The invention relates to the use of a bacterial artificial chromosome (bac) for the preparation of a vaccine, wherein the bac comprises an inducible bacterial ori sequence for amplification of the bac to more than 10 copies per bacterial cell. Plus a viral expression cassette comprising a cdna of an attenuated rna virus genome and comprising cis-regulatory elements for transcription of said viral cdna in mammalian cells and for processing of the transcribed rna into infectious viral rna..
Katholieke Universiteit Leuven


07/21/16
20160206711 
 Treatment of mammalian physiological reaction of ige antibodies present in said mammal upon contact with the corresponding antigen patent thumbnailTreatment of mammalian physiological reaction of ige antibodies present in said mammal upon contact with the corresponding antigen
A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of ige antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (cnt) derived from clostridia sp.. .

07/21/16
20160206705 

Antiviral activity of gas6 inhibitor


Compositions and methods are provided for treating viral infection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits axl, mer or tyro3 protein activity, for example by inhibition of the binding interaction between axl, mer or tyro3 and its ligand gas6.. .
Ruga Corporation


07/21/16
20160206704 

Method


A method of using a vector comprising a transgene to treat a disease or condition of the eye, the method comprising the steps: (a) administering a solution to a mammalian subject by subretinal injection in an amount effective to at least partially detach the retina to form a subretinal bleb, wherein the solution does not comprise the vector; and (b) administering a medicament composition by subretinal injection into the bleb formed by step (a), wherein the medicament comprises the vector and is injected in an amount effective to treat the disease or condition; wherein the transgene is expressible in cells of the mammalian subject.. .
Isis Innovation Limited


07/21/16
20160206698 

Use of compounds with thrombopoietic activity to promote bone growth and healing


Tpo was used to promote the growth of bone in both rats and in mice. Gaps in both mouse and in rat bones were treated with a scaffold sized to fit the gap.
Indiana University Research & Technology Corporation


07/21/16
20160206668 

Production of probiotics by in vitro enrichment of beneficial microorganisms from human or animal microbiota


The present invention is directed to a method of treating a dysbiosis in a mammal, preferably a human, by taking a sample of the micro-organisms that are causative of the dysbiosis, whereafter said sample is enriched in vitro for healthy bacteria, after which the sample is replaced.. .
Nederlandse Organisatie Voor Toegepast-natuurwetenschappelijk Onderzoek Tno


07/21/16
20160206665 

Encapsulated cells for hormone replacement therapy


A composition comprising microcapsules, the microcapsules containing both live mammalian ovarian granulosa cells and live mammalian ovarian theca cells, is described. In some embodiments, the granulosa cells and the theca cells are contained in separate microcapsules in the composition; in some embodiments, the granulosa cells and the theca cells are contained together in the same microcapsules in the composition the composition is can be used for estrogen, and optionally also progesterone, delivery, and hence is preferably free or essentially free of oocytes.
Wake Forest University Health Sciences


07/21/16
20160206625 

Molybdenum compounds for use in the treatment of cyanide poisoning


The present invention relates to compositions comprising molybdenum compounds, novel molybdenum compounds, kits and methods for their preparation. In particular, the present invention relates to compositions comprising molybdenum compounds for use in the treatment of cyanide poisoning in mammals, in particular humans..
HÁskÓli Íslands


07/21/16
20160206608 

Crizotinib for use in the treatment of cancer


The present invention relates to the use of ros kinase inhibitors for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ros.
Pfizer Inc.


07/21/16
20160206598 

Therapeutic agent for dyslipidemia


This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemia states, such as hyper-ldl cholesterolemia, in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, said drug composition comprising the following: (r)-2-[3-[[n-(benzoxazole-2-yl)-n-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate of either; and an omega-3 fatty acid or an ester derivative of an ω-3 fatty acid..
Kowa Company, Ltd.


07/21/16
20160206597 

New use


The present invention relates to methods and pharmaceutical compositions for renal protection in a mammal in need thereof, such as a mammal having a disease manifested by atrial enlargement and/or remodeling or suffering from hypertension or heart failure or being prone to suffering from hypertension and/or heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an angiotensin receptor neprilysin inhibitor (arni) or of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi) or with a nepi pro-drug to said mammal.. .

07/21/16
20160206576 

N-acetylcysteine amide (nac amide) in the treatment of diseases and conditions associated with oxidative stress


Methods and compositions comprising n-acetylcysteine amide (nac amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of nac amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione..

07/21/16
20160206558 

Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic


Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“gi”) of a mammal for an extended period of time..
Depomed, Inc.


07/21/16
20160206543 

Synergistic compositions and methods for mitigating skin irritation and enhancing skin barrier function


Methods and compositions are provided for mitigating the irritation of mammalian skin cells, protecting cell viability and/or enhancing cell-cell junction, thus improving skin barrier function. The compositions contain combinations of acetyl hexapeptides and a cosmetically and/or pharmaceutically acceptable carrier.
Gojo Industries, Inc.


07/21/16
20160206479 

Easy removal adhesive article


An elongate adhesive article having a length substantially greater than a width includes a backing layer having an adhesive layer and a single weakened region formed of a removable strip of backing layer that is oriented substantially perpendicular to the article length. The removable strip of backing layer is at least partially defined by a pair of lines of weakness separated by a gap of between about 2 and about 15 mm.
Johnson & Johnson Consumer Inc.


07/21/16
20160206324 

Devices, systems, and methods to precondition, arterialize and/or occlude a mammalian luminal organ


Devices, systems, and methods to precondition, arterialize, and/or occlude a mammalian luminal organ. In an exemplary embodiment of a device for preconditioning, arterializing, and/or occluding a mammalian luminal organ of the present disclosure, the device comprises a frame comprising a plurality of struts, wherein at least one strut of the plurality of struts forms a local general perimeter or boundary of the device, and an expandable occluder coupled to the frame and comprising a membrane or other expandable material that can generally expand and/or unfold as device shifts from a first configuration to a second configuration..
Cvdevices, Llc


07/14/16
20160202241 

Nanofibrous photoclickable hydrogel microarrays


Nanofibrous hydrogel microarray systems that act as facile, high throughput platforms for in vitro drug discovery and investigation and screening of combinatorial effects of physical and biochemical cues on maturation and differentiation of mammalian cells.. .
The Regents Of The University Of Colorado, A Body Corporate


07/14/16
20160201055 

Methods, systems, and compositions relating to mirna-146a


Some embodiments comprise methods, systems, and compositions to promote, improve and/or increase neuronal differentiation, oligodendrocyte differentiation, or neurological outcome or function in a patient in need thereof. Some embodiments also comprise the administration a composition comprising a pharmaceutically effective amount of one or more of a group comprising microrna-146a, a promoter of microrna-146a expression, a microrna-146a mimic, thymosin beta 4, and a phosphodiesterase 5 inhibitor to treat neurological conditions, disease, or injury in mammals, including in human beings..
Henry Ford Health System


07/14/16
20160201033 

Hematopoietic cell e-selectin/l-selectin ligand polypeptides and methods of use thereof


The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal.. .

07/14/16
20160200817 

Methods of identifying anti-inflammatory compounds


A mammalian c-type lectin receptor type is identified which is shown to bind igg antibodies or fc fragments, thus inducing ivig-related reversal of inflammation associated with various immune disorders. The identification of a dc-sign receptor type which interacts with igg to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a dc-sign(+) cell to signal a second effector macrophage, causing an increase in expression of the fcγriib receptor and in turn inhibiting a cellular-mediated inflammatory response..
The Rockefeller University


07/14/16
20160200814 

Immunoreceptor modulation for treating cancer and viral infections


A method of reducing or relieving immune inhibition in a mammal includes the step of at least partly inhibiting or reducing cd96 activity in one or more cells of the mammal to thereby relieve immune inhibition and/or enhance or restore immune surveillance in the mammal. Typically, inhibiting or reducing cd96 activity does not include, or depend upon, killing of cd96-expressing cells in the mammal.
The Council Of The Queensland Institute Of Medical Research


07/14/16
20160199648 

System and animal-human neural interface


Aspects of the invention include system and method for transmitting neural data extracted from an electrical signal of a non-human mammal to a human. The system includes an electrode implantable into the animal auditory nerve, brainstem, or midbrain of the non-human mammal, configured to record the electrical signal of the non-human mammal, the electrical signal being in the form of sequences of pulses or pulse trains encoding frequency information of the non-human mammal, a processing device electrically coupled with the electrode, configured to process the electrical signal and convert the processed electrical signal into a digital signal, a transmitting device electrically coupled with the processing device, configured to transmit the digital signal, and a receiving device electrically coupled with the transmitting device, configured to receive the transmitted digital signal, convert the received digital signal into a sensory output perceptible to the human, and apply the sensory output to the human..
Northwestern University


07/14/16
20160199530 

Bioresorbable wound dressing


The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues.
Carl Freudenberg Kg


07/14/16
20160199506 

Compounds that participate in cooperative binding and uses thereof


The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the fkbp family, a member of the cyclophilin family, or pin1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the fkbps or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins.
Warp Drive Bio, Llc


07/14/16
20160199490 

Trans carotenoids, their synthesis, formulation and uses


The invention relates to trans carotenoid compounds and salts thereof as well as compositions thereof, methods for making them, and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans..
Diffusion Pharmaceuticals, Llc


07/14/16
20160199435 

Methods for preventing or treating metabolic syndrome


The invention provides methods of preventing or treating metabolic syndrome in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof..

07/14/16
20160199422 

Compositions and methods for treatment of cancer using bacteria


Provided herein are compositions comprising substantially non-viable gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer.
Decoy Biosystems, Inc.


07/14/16
20160199414 

Use of mesenchymal stem cells for the treatment of oral inflammation


Provided are methods employing of mesenchymal stem cells (mscs) to prevent, mitigate and/or reverse oral inflammatory conditions, particularly chronic, recalcitrant, unresponsive and/or persistent oral inflammatory conditions, including chronic gingivostomatitis, in a mammal. Methods for preparation of the mscs are also provided..
The Regents Of The University Of California


07/14/16
20160199401 

Methods and compositions for treating neuropathies


Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons.
Washington University


07/14/16
20160199340 

Calebin a for hepatic steatosis


The present invention discloses the potential of calebin a in attenuating high fat diet (hfd) induced hepatic steatosis in mammals.. .

07/14/16
20160199298 

Fosfestrol for use in curative or palliative treatment of cancer in female mammals


The present invention concerns the use of fosfetrol (diethylstilbestrol diphosphate) in a method of curative or palliative treatment of cancer in female mammals, said method comprising orally administering fosfestrol in a daily dosage of at least 500 mg. Examples of cancers that can be treated by the present method include breast cancer, endometrium cancer and ovarian cancer.
Chamaeleo Pharma Bvba


07/07/16
20160195549 

Biomarkers for seizures


The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject.
The Trustees Of The University Of Pennsylvania


07/07/16
20160194664 

Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination


In one aspect, the present invention provides an intron-modified capsid expression cassette useful for generating adeno-associated virus (aav) vector particles. In another aspect, the present invention provides a method of reducing the immune response in a mammalian subject undergoing treatment with an aav vector..
Fred Hutchinson Cancer Research Center


07/07/16
20160194660 

Expression vectors for recombinant protein production in mammalian cells


The invention provides expression vectors that support high levels of polypeptide expression in mammalian cells. The vectors contain at least one expression cassette for a target polypeptide; an expression cassette for a eukaryotic selectable marker protein; an expression cassette for a bacterial selectable marker protein, and a bacterial plasmid origin of replication..
Merck Sharp & Dohme Corp.


07/07/16
20160194616 

Anaplastic lymphoma kinase (alk) as an oncogene capable of transforming normal human cells


The present invention provides compositions and methods for transforming primary mammalian cells using an oncogenic form of alk wherein the transformed cells display features of that of a corresponding tumor cell isolated from a cancer subject. The invention also provides a method for immortalizing normal cd4+ t lymphocytes with a lymphoma-characteristic form of alk such as npm-alk..
The Trustees Of The University Of Pennsylvania


07/07/16
20160194376 

Hematopoietic cell selectin ligand polypeptides and methods of use thereof


The invention feature methods and compositions for treating inflammatory disorders, hematopoietic disorders and non-hematopoietic disorders (e.g., non-hematopoietic cancers) and for isolating cells (e.g., stem cells) in a mammal.. .

07/07/16
20160194342 

Phenicol antibacterials


The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.. .
Zoetis Services Llc


07/07/16
20160193464 

Neurological prosthesis


A method improving or restoring neural function in a mammalian subject in need thereof is disclosed, the method including: using an input receiver to record an input signal generated by a first set of nerve cells; using an a encoder unit including a set of encoders to generate a set of coded outputs in response to the input signal; using the encoded outputs to drive an output generator; and using an output generator to activate a second set of nerve cells wherein the second set of nerve cells is separated from the first set of nerve cells by impaired set of signaling cells. In some embodiments, the second set of nerve cells produces a response that is substantially the same as the response in an unimpaired subject..
Cornell University


07/07/16
20160193363 

Imaging brown adipose tissue with curcumin derivatives


Methods and compositions for imaging brown adipose tissue (bat) in living mammals, e.g., humans.. .
The General Hospital Corporation


07/07/16
20160193351 

Conjugate based systems for controlled drug delivery


Conjugates which comprise a drug and a ligand which includes a first saccharide; wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the conjugate is sensitive to serum concentration of a second saccharide. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation..
Smartcells, Inc.


07/07/16
20160193308 

Dpp-4-targeting vaccine for treating diabetes


The present invention provides a vaccine for the prophylaxis or treatment of diabetes using a polypeptide containing the amino acid sequence shown by seq id no: 2 or an amino acid sequence of a non-human mammal, which corresponds to seq id no: 2, and the like as an immunogen, which induces a neutralizing antibody to dpp-4, and a prophylactic or therapeutic agent for diabetes, which contains a ddp-4 neutralizing antibody that recognizes a partial amino acid sequence of the aforementioned ddp-4.. .
Osaka University


07/07/16
20160193304 

Process for concentration of a polypeptide


The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.. .
Shire Pharmaceuticals Ireland Limited


07/07/16
20160193264 

Composition comprising nettle


The present invention provides compositions which include one or more oils and oleum coctus urticae. The present invention also provides methods for preparing such compositions and treatment and/or prevention of skin diseases and physiological degenerative processes of the skin in mammals by using such compositions alone or in combination with excipients and as a co-adjuvant in combination with other therapies..
Pandela S.r.l.


07/07/16
20160193248 

Methods for improving respiratory system health and increasing the concentration of hypothiocyanate ion in vertbrate lungs


The present disclosure relates to methods and devices to improve respiratory system health, increase resistance to infection, and increase the hypothiocyanate ion in mammalian lungs. The methods generally comprise: generating a hydrogen peroxide gas that is non-hydrated and free of ozone, and directing the gas comprising primarily hydrogen peroxide gas into an environment and exposing a subject to the environment such that the hydrogen peroxide gas acts to the increase of the hypothiocyanate ion in mammalian lungs..

07/07/16
20160193247 

Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal


The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions thereof.
Relypsa, Inc.


07/07/16
20160193232 

Treatment and prevention of mastitis


Treating and/or preventing clinical mastitis includes administering a cationic steroidal anti-microbial (csa) formulation to the intra-mammary organ of a mammal (e.g., a dairy cow), such as by injection into the mammary organ and/or topical application. The csa formulation can be effective in treating and/or preventing mastitis caused by gram positive bacteria, gram negative bacteria, fungus, and/or prototheca.
Brigham Young University


07/07/16
20160193208 

Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha


The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (nsclc) in which platelet-derived growth factor receptor alpha (pdgfrα) is expressed and is driving the disease, and provides methods for identifying a mammalian nsclc tumor that belongs to a subset of nsclc tumors in which pdgfrα is expressed, and for identifying a nsclc tumor that is likely to respond to a pdgfrα-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian nsclc tumor in which pdgfrα is expressed, and for determining whether a compound inhibits the progression of a pdgfrα-expressing mammalian nsclc tumor..
Cell Signaling Technology, Inc.


06/30/16
20160187511 

Pulsed marine source


Systems and methods for generating seismic signal include using a conventional airgun array and specifically detunes the timing of the array so individual airguns are not fired at the same time and with their interacting bubbles form a unique composite pulse that can be separated by various means out of a seismic record to form the shotpoint. The advantage of this approach is a lower overall noise envelope in the water minimizing impact on the marine mammals and it allows multiple arrays to be fired in close spatial and timing proximity with minimal to no interference..

06/30/16
20160187341 

Keratins as biomarkers for cervical cancer and survival


The current disclosure provides methods for detecting and analyzing krt4 and krt17 expression in a sample obtained from a test subject. The current disclosure pertains to methods and kits for identifying a mammalian subject with cervical cancer or non-cancerous lesions of the cervix.

06/30/16
20160186208 

Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal


The invention is directed to a method of mutating one or more target nucleic acid sequences in a stem cell or a zygote comprising introducing into the stem cell or zygote (i) ribonucleic acid (rna) sequences that comprise a portion that is complementary to a portion of each of the target nucleic acid sequences and comprise a binding site for a crispr associated (cas) protein; and a cas nucleic acid sequence or a variant thereof that encodes a cas protein having nuclease activity. The stem cell or zygote is maintained under conditions in which the target nucleic acid sequences are mutated in the stem cell or zygote.

06/30/16
20160186196 

Method and composition for generating programmed cell death resistant algal cells


The present invention provides transgenic algal cells resistant to programmed cell death (pcd) and methods and compositions useful in generating such cells. Specifically, the invention utilizes expression of one or more mammalian anti-apoptotic genes in algal cells to promote resistance to pcd, which is useful for stress tolerance and increased cell viability and biomass production during cultivation..

06/30/16
20160186183 

Methods and compositions for treating malignant tumors associated with kras mutation


This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with kras mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the kras gene, and (ii) an aberrant expression level of kras protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more rnai molecules that are active in reducing expression of gst-π.. .

06/30/16
20160186173 

C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders


Provided herein are antisense oligonucleotides that can effectively prevent or decrease c-myc protein expression as well as decrease overall rates of cell proliferation in in vitro and mammalian in vivo models of cell proliferative disorders as well as methods for using the same.. .

06/30/16
20160186170 

Compositions and methods for induced tissue regeneration in mammalian species


Aspects of the present invention include methods and compositions related to the modulation of molecules regulating the regenerative potential of cells and tissues in the embryonic state and the loss thereof in later fetal and adult stages of development. Said methods and compositions have uses in research in stem cell biology and in increasing regenerative potential in fetal and adult tissues otherwise incapable of regeneration..

06/30/16
20160186142 

Mammalian muscle-derived stem cells


The present invention provides a new method of obtaining muscle-derived mesenchymal stem cells from microbiopsies of mammalian origin. The invention provides for a minimally invasive methodology yielding high amounts of mscs that can differentiate into different cell lineages..

06/30/16
20160186139 

Cell and gene based methods to improve cardiac function


Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit r1-encoding nucleic acid sequence and a ribonucleotide reductase subunit r2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium.

06/30/16
20160186130 

Cell culture improvements


The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture..

06/30/16
20160185832 

Compositions and methods for treatment of disorders related to cep290


Compositions are provided that comprise a recombinant vector carrying a nucleic acid sequence encoding a fragment of cep290 lacking all or part of its n-terminal and c-terminal inhibitory regions, under the control of regulatory sequences which express the product of said gene in a selected cell of a mammalian subject, and a pharmaceutically acceptable carrier. These and other compositions are disclosed with are useful in methods for treating a mammalian subject having a disease associated with a cep290 mutation, such as lebers congenital amaurosis..

06/30/16
20160184413 

Formulation for stabilizing proteins, which is free of mammalian excipient


The present invention pertains to a formulation comprising a hydrophilic polymer, a mixture of a polyalcohol and a sugar, wherein the weight ratio of polyalcohol to sugar is between 2:1 to 5:1 (wt-%), a detergent, wherein the formulation is free of stabilising proteins.. .

06/30/16
20160184320 

Bioavailable solid state (17-ss;)-hydroxy-4-androsten-3-one esters


Disclosed are bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-β)-hydroxy-4-androsten-3-one.. .

06/30/16
20160184289 

Compositions containing aromatic aldehydes and their use in treatments


Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions.

06/30/16
20160184280 

Methods of preventing the development of mucositis and related disorders


Disclosed is a method of preventing the development of mucositis in a subject undergoing radiation therapy or chemotherapy for a disease in need thereof comprising administering an effective amount of a mammalian target of rapamycin (mtor) inhibitor, such as rapamycin, to the subject. Further disclosed is a method of increasing the lifespan of a normal oral keratinocyte and/or reducing oxidative stress in a normal epithelial cell, wherein the method comprises administering an effective amount of an mtor inhibitor to a subject undergoing radiation therapy or chemotherapy for a disease in need thereof..

06/30/16
20160184276 

Sphingosine kinase inhibition for the treatment and prevention of obstetrical disorders


The subject invention is directed to the treatment of obstetrical disorders by administration of a sphingosine kinase inhibitor. Spingosine kinase inhibitors are useful in the management or treatment of obstetrical disorders resulting from inflammation such as preterm birth and preterm labor.

06/30/16
20160184262 

4-methylumbelliferone treatment for immune modulation


Compositions for treating autoimmune, allergic, or atopic disease comprising a compound that inhibits hyaluronan synthesis and a pharmaceutically acceptable carrier are described. In some embodiments, the compound that inhibits hyaluronan synthesis is 4-methylumbelliferone or a metabolite of 4-methylumbelliferone.

06/30/16
20160184245 

Formulations for epidermal repair


The present disclosure is directed to dermatological formulations and their use for treating a variety of dermatological diseases and disorders, and for repairing and restoring a disrupted epidermal barrier, inhibiting inflammation, restoring a proper environment for maintaining a balanced symbiotic microbiome, and inhibiting the growth of pathogenic microorganisms in the epidermis—the outer layer of mammalian skin.. .

06/30/16
20160184242 

Use of cysteamine and derivatives thereof to suppress tumor metastases


The present disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein..

06/30/16
20160183859 

System and detecting amyloid proteins


In accordance with an embodiment of the invention, there is provided a device and method for detecting an amyloid protein in an eye of a mammal. A method comprises illuminating the eye with a light source having at least one of a wavelength property, a polarization property or a combination thereof, each appropriate to produce fluorescence in at least an amyloid-binding compound when the amyloid-binding compound is bound to the amyloid protein, the amyloid-binding compound having been introduced to the eye and specifically binding to the amyloid protein indicative of the amyloidogenic disorder; and determining a time decay rate of fluorescence for at least the fluorescence produced by the amyloid-binding compound bound to the amyloid protein, the determining permitting distinguishing of the presence of the amyloid-binding compound bound to the amyloid protein in the eye based on at least the time decay rate..

06/30/16
20160183822 

Non-invasive characterizing cardiovascular systems


The present disclosure uses physiological data, ecg signals as an example, to evaluate cardiac structure and function in mammals. Two approaches are presented, e.g., a model-based analysis and a space-time analysis.

06/23/16
20160177361 

Methods of culturing a mammalian cell


Provided herein are methods of culturing a mammalian cell in a liquid medium including poloxamer-188 at a concentration of 1.8 g/l or at a greater concentration than 1.8 g/l more or a liquid medium that includes a poloxamer-188 concentration that is selected based on one or more factors selected from the group of: pore size, pore type, gas flow rate, viable cell density in the medium, and markers related to cell stress.. .

06/23/16
20160177310 

Conserved hbv and hcv sequences useful for gene silencing


Conserved consensus sequences from known hepatitis b virus strains and known hepatitis c virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of hbv and hcv, thereby providing therapeutic utility against hbv and hcv viral infection in humans..

06/23/16
20160177300 

Means and methods for the generation of mammalian producer cells for the production of recombinant proteins


The present invention relates to the generation of mammalian cells capable of producing proteins at an industrial scale and means and methods to obtain and use said cells, in particular for protein production.. .

06/23/16
20160177271 

Combinational use of mechanical manipulation and programin to generate pluripotent stem cells from somatic cells


The present invention provides methods and compositions for inducing pluripotency in differentiated mammalian cells. In particular, the methods include mechanically aggregating the cells into discrete masses or embryoid-like bodies and treated them with a small molecule compound.

06/23/16
20160176967 

Methods and materials for treating cancer


This document provides methods and materials involved in treating cancer. For example, methods and materials for identifying a mammal as having an elevated level of pd-1+/cd11ahigh cd8 t cells having the potential to exert anti-cancer effects are provided.

06/23/16
20160176944 

Oligomeric receptor ligand pair member complexes


This invention concerns an oligomeric receptor-ligand pair member in general and an oligomeric mhc-peptide complex in particular and a method of labeling, detecting and separating mammalian t cells according to the specificity of their antigen receptor by use of the oligomer. The invention further concerns a method of targeting the oligomeric receptor-ligand pair member complexes to target molecules of the surface of a target cell in order to present antigens on the target cell.

06/23/16
20160176913 

Preparation and uses of obeticholic acid


Or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a fxr mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing hdl cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.

06/23/16
20160176851 

Antagonists of prostaglandin ep3 receptor


Provided herein are antagonists of prostaglandin ep3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.. .

06/23/16
20160176843 

Substituted amino triazoles useful as acidic mammalian chitinase inhibitors


Disclosed are amino triazole compounds substituted by a carboxylate functional group or an bioisosteric polar functional group. Compounds having the carboxylate moiety or carboxylate bioisostere inhibit acidic mammalian chitinase.

06/23/16
20160175586 

Epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury


Methods are described comprising: administering to a mammal with a paralysis an electrical enabling motor control stimulation to at a sub-threshold location, wherein the electrical enabling motor control stimulation provides spontaneous voluntary movement of at least one body part.. .

06/23/16
20160175501 

Guidewire system and pump installation using same


In one embodiment, the present invention is a method of positioning in a mammalian heart of a patient a blood pump including an inflow cannula, a pump housing and an outflow cannula, the method including forming an incision in a low-pressure location on the heart wall; passing the outflow cannula of the blood pump through the incision and into a left ventricle of a heart; positioning a tip of a guidewire into an aorta, distal to an aortic valve; advancing the tip through the aortic valve and into the left ventricle; connecting the tip to the outflow cannula; pulling the blood pump with the guidewire to advance at least a portion of the outflow cannula through the aortic valve and into the aorta; securing the blood pump to the heart, the aorta, or both; disconnecting the tip from the blood pump; and removing the guidewire from the patient.. .

06/23/16
20160175382 

Compositions and methods for inducing urinary voiding and defecation


Methods, pharmaceutical formulations, and kits are provided for using neurokinin 2 receptor agonists to effectuate voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing voiding of urine and defecation in mammals that do not have a voiding dysfunction such as, for example, in a person who is comatose and may void unconsciously or in a pet at a convenient location at a specific time.

06/23/16
20160175379 

Combination therapy for the treatment of ischemia-reperfusion injury


The present technology provides methods of preventing or treating an ischemia-reperfusion injury, such as acute myocardial infarction injury, in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and a second active agent to subjects in need thereof..

06/23/16
20160175373 

Composition for treating diabetes and dyslipidemia obtained from the extract of costus pictus d.don plant and a preparing the same


The disclosure provides a medicinal composition for treating diabetes and dyslipidemia obtained from the extract of costus pictus d. Don.

06/23/16
20160175328 

Compositions and treatments of heart failure in non-human mammal animals


The invention relates to new compositions comprising an aldosterone antagonist according to a particular posology for the treatment of heart failure in non-human mammal animals.. .

06/23/16
20160175293 

Pim kinase inhibitor combinations


The present invention relates to a pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a jak inhibitor compound, (b) a pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human..

06/23/16
20160175091 

Systems, devices, and/or methods for managing implantable devices


Certain exemplary embodiments can provide a system, machine, device, manufacture, circuit, composition of matter, and/or user interface adapted for and/or resulting from, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise and/or relate to, via a device implanted in a mammal, sensing a ciliary muscle movement and/or force and/or converting the ciliary muscle movement and/or force to a signal and/or a predetermined form of power.. .

06/23/16
20160174532 

Genetically modified rat models for pain


This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered nervous system function. In one aspect, the altered function results in pain in the mammal.

06/16/16
20160170060 

Monitoring system, components, methods, and applications


A real-time, marine acoustic monitoring system and method for detecting, tracking, recording, analyzing, communicating and otherwise obtaining and manipulating data indicative of marine presence and/or activity, and using such data to avoid or mitigate detrimental impact on the marine environment. The system includes sub-sea instrumentation packages (sps) including sensors recording acoustic signals and other sensor data that allow elapsed and/or real-time, in-situ data communications and control of the individual instrumentation packages and system configuration.
Fairfield Industries Incorporated D/b/a Fairfieldnodal


06/16/16
20160168588 

Methods of producing long acting ctp-modified polypeptides


Disclosed herein is a method for manufacturing a recombinant polypeptide of interest modified by a ctp extension in a mammalian cells culture system.. .
Opko Biologics Ltd


06/16/16
20160168572 

Delivery of therapeutic agent


A method of producing nanovesicles comprising an oligonucleotide inhibitor to an oncogene or a proto-oncogene or the gene product thereof, said method comprises a) introducing a dna sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell; b) allowing the cell to express said inhibitor oligonucleotide; and c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell. Nanovesicles produced by the claimed method can be effectively and specifically targeted to e.g.
Vl27,inc.


06/16/16
20160168533 

Isolation, expansion and use of clonogenic endothelial progenitor cells


A hierarchy of endothelial colony forming cells (epcs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential-endothelial colony forming cell (hpp-ecfc) was isolated and characterized.
Indiana University Research And Technology Corporation


06/16/16
20160168227 

Composition and vaccine for treating lung cancer


The present invention relates to a composition comprising at least one mrna encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5t4 (trophoblast glycoprotein, tpbg), survivin (baculoviral tap repeat-containing protein 5; birc5), ny-eso-1 (new york esophageal squamous cell carcinoma 1, ctag1b), mage-c1 (melanoma antigen family c1), mage-c2 (melanoma antigen family c2), and muc1 (mucin 1). The invention furthermore relates to a vaccine comprising at least one mrna encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (nsclc), and diseases or disorders related thereto.
Curevac Ag


06/16/16
20160168105 

Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide


Provided are pharmaceutical compositions and dosage forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders treatable or preventable by inhibition of a jnk pathway in mammals using such pharmaceutical compositions or dosage forms.
Signal Pharmaceuticals, Llc


06/16/16
20160166845 

Dynamic multi-layer therapeutic magnetic device


A multi-layer magnetic device comprising two or more layers of containing magnets or ferromagnetic material to be applied to areas of the body of a mammal in which the first layer has one or more protrusions and the second layer has one or more receiving zones that are positioned to align with the protrusions of the first layer. At least a portion of the first layer has a first magnetic pattern, and at least a portion of the second layer has a second magnetic pattern such that, when the protrusions are aligned with the receiving zones, at least one region of the first magnetic pattern faces at least one region of the second magnetic pattern of like polarity thereby repulsing one another..
Nikken International, Inc.


06/16/16
20160166754 

Unitary body systems and devices and methods to use the same for retroperfusion


Unitary body systems and devices and methods to use the same for retroperfusion. In an exemplary device embodiment of the present disclosure, the device comprises a unitary body having a wall and a lumen defined therethrough, a first portion terminating at a first end and configured for at least partial placement within a mammalian artery, a first one-way valve positioned at or near an end of the first portion opposite the first end, a second portion terminating at a second end and configured for at least partial placement within a mammalian vein, and a second one-way valve positioned at or near an end of the second portion opposite the second end..
Cvdevices, Llc


06/16/16
20160166735 

Injectable composition for in-situ repair and regeneration of an injured ligament or tendon and methods of use


The invention provides an injectable composition and method for the minimally invasive, in-situ repair and regeneration of an injured ligament or tendon in a mammalian subject. The composition is also useful for the delivery of growth factors, therapeutic agents and cells into the area of tendon or ligament injury..
The Board Of Trustees Of The Leland Stanford Junior University


06/16/16
20160166730 

Biocompatable annular prostheses and methods for forming same


Annular prostheses comprising an elongated tubular member formed from an extracellular matrix (ecm) composition comprising ecm from a mammalian tissue source, which, when disposed proximate damaged cardiovascular tissue, induces modulated healing, including modulation of inflammation and bioremodeling. The ecm can also be augmented with a supplemental biologically active agent, such as a growth factor, to enhance modulation of inflammation and bioremodeling..
Cormatrix Cardiovascular, Inc.


06/16/16
20160166718 

Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease


Disclosed are agents (e.g., peptides, polypeptides, proteins, small molecules, antibodies, and antibody fragments that target senescent cells) and methods of their use for imaging senescent cells in vivo and for treating or preventing cancer, age-related disease, tobacco-related disease, or other diseases and disorders related to or caused by cellular senescence in a mammal. The methods include administering one or more of the agents of the invention to a mammal, e.g., a human.
Unity Biotechnology, Inc.


06/16/16
20160166710 

Method for increasing expression of rna-encoded proteins


The invention relates to an rna comprising at least one open reading frame (orf) and comprising at least one modification, which increases the expression of the encoded peptide or protein. Furthermore, the invention relates to the medical use of such a modified rna administered to a subject by jet injection.
Curevac Ag


06/16/16
20160166709 

Methods and compositions for treating brain diseases


The present disclosure provides methods of treating a disease or delivering a therapeutic agent to a mammal comprising administering to the mammal's cisterna magna and/or ventricle an raav particle containing a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of aav inverted terminal repeats in a manner such that cells with access to the cerebrospinal fluid (csf) express the therapeutic agent and in certain embodiments secretes the therapeutic agent into the csf for distribution to the brain.. .
University Of Iowa Research Foundation


06/16/16
20160166668 

Composition and vaccine for treating prostate cancer


The present invention relates to a composition comprising at least one mrna encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of psa (prostate-specific antigen), psma (prostate-specific membrane antigen), psca (prostate stem cell antigen), steap (six transmembrane epithelial antigen of the prostate), muc1 (mucin 1) and pap (prostatic acid phosphatase). The invention furthermore relates to a vaccine comprising at least one mrna encoding such a combination of antigens and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (pca), preferably of prostate adenocarcinoma, locally limited, locally advanced, metastatic, castration-resistant (hormone-refractory), metastatic castration-resistant and non-metastatic castration-resistant prostate cancers, and diseases or disorders related thereto.
Curevac Ag


06/16/16
20160166662 

Use of attenuated strains of parasites for the prevention or treatment of pathologies associates with an apicomplexan


Strains of sarcocystidae selected from toxoplasma spp or neospora spp isolated from their natural environment and having an immunostimulant effect, for the use thereof in the prevention or the treatment, in a mammal, of a pathology associated with an apicomplexan of the family cryptosporidiidae.. .
Universite Francois Rabelais De Tours


06/16/16
20160166652 

Novel n- and c-terminal substituted antagonistic analogs of gh-rh


There is provided a novel series of synthetic analogs of hgh-rh(1-29)nh2 (seq id no: 1) and hgh-rh(1-30)nh2. Of particular interest are those carrying phac, n-me-aib, dca, ac-ada, fer, ac-amc, me-nh-sub, phac-ada, ac-ada-d-phe, ac-ada-phe, dca-ada, dca-amc, nac-ada, ada-ada, or ch3—(ch2)10—co-ada, at the n-terminus and β-ala, amc, apa, ada, ae2a, ae4p, ε-lys(α-nh2), agm, lys(oct) or ahx, at the c-terminus.
U.s.a., Represented By The Department Of Veterans Affairs


06/16/16
20160166633 

Methods and compositions for the prevention and treatment of friedreich's ataxia


The disclosure provides methods of preventing or treating friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with friedreich's ataxia, and/or reducing the likelihood or severity of friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof..
Stealth Bio Therapeutics Corp


06/16/16
20160166626 

Topical compositions and methods for reducing oxidative stress


A composition for the topical application on a mammalian skin comprises one or more brassica plant extracts selected from the group consisting of: brassica juncea extract, brassica oleracea italica extract, brassica oleracea capitata extract, brassica oleracea botrytis extract, and brassica oleracea acephala extract. The composition further comprises one or more selected from the group consisting of: curcuma longa extract, curcuminoids, tetrahydrocurcuminoids, metabolites of curcuminoids or tetrahydrocurcuminoids, and derivatives of curcuminoids or tetrahydrocurcuminoids.
Lifevantage Corporation


06/16/16
20160166620 

Encapsulated cells for hormone replacement therapy


A composition comprising microcapsules, the microcapsules containing both live mammalian ovarian granulosa cells and live mammalian ovarian theca cells, is described. In some embodiments, the granulosa cells and the theca cells are contained in separate microcapsules in the composition; in some embodiments, the granulosa cells and the theca cells are contained together in the same microcapsules in the composition.
Wake Forest University Health Sciences


06/16/16
20160166618 

Treatment of pain using amnion derived adherent cells


Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent amnion-derived cells (amdacs). Because mammalian placentas are plentiful and are normally discarded as medical waste, they represent a unique source of medically-useful stem cells..
Anthrogenesis Corproation


06/16/16
20160166557 

Antiviral agents


A pharmaceutically acceptable salt thereof or solvate thereof or mixtures thereof. The subject can be an animal, particularly mammals and more particularly humans and companion animals such as cats and dogs..

06/16/16
20160166417 

Gastric restriction devices for treating obesity


A gastric restraining device for treating excessive weight or obesity in mammals. The gastric restraining device includes an elastomeric sheet configured to be placed around a stomach of a mammal, an ablation device attached to the elastomeric sheet, the ablation device configured to emit energy toward an outer surface of the stomach when the elastomeric sheet is placed around the stomach, and an energy device coupled to the ablation device to generate the energy and to transfer the energy to the ablation device..

06/16/16
20160166387 

Implantable lubrication device and treating a human or mammal patient by means of the device


A lubrication device for lubricating a joint of a human or mammal patient, which is entirely implantable in a patient's body, comprises a reservoir for storing a lubricating fluid and a fluid connection for introducing the lubricating fluid into the joint when the device is implanted in the patient's body. Further, the fluid connection comprises a fluid connection device connecting the reservoir with the joint such that a lubricating fluid flow is established from the reservoir into the joint.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.7745

4929

2 - 1 - 117